IMMUNITYBIO, INC. Debt Instrument, Convertible, Conversion Price
IMMUNITYBIO, INC. (IBRX) had Debt Instrument, Convertible, Conversion Price of $1.29 per share as of 2023-09-11, per its 10-K filed 2026-02-23.
Financial Statements › Notes
us-gaap:DebtInstrumentConvertibleConversionPrice1 · last filed 2026-02-23
- 2023-09-11: Debt Instrument, Convertible, Conversion Price $1.29.
- 2022-12-12: Debt Instrument, Convertible, Conversion Price $5.67.
| Period end | Debt Instrument, Convertible, Conversion Price |
|---|---|
| 2023-09-11 | $1.29 10-K · filed 2026-02-23 |
| 2022-12-12 | $5.67 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |